Patient characteristics
| . | Overall population (n = 206) . | |
|---|---|---|
| . | No. . | % . |
| Age (years) at diagnosis | ||
| Median (range) | 48.0 (16.0-60.0) | |
| <30 | 21 | 10.2 |
| 30 to <40 | 36 | 17.5 |
| 40 to <50 | 59 | 28.6 |
| 50-60 | 90 | 43.7 |
| Sex | ||
| Male | 101 | 49.0 |
| Female | 105 | 51.0 |
| WHO-ECOG performance status | ||
| 0 | 122 | 59.2 |
| 1 | 74 | 35.9 |
| 2 | 7 | 3.4 |
| 3-4 | 3 | 1.5 |
| WBC (×109L) at diagnosis | ||
| Median (range) | 24.7 (0.5-312.5) | |
| <25 | 104 | 50.5 |
| 25-99.9 | 69 | 33.5 |
| ≥100 | 33 | 16.0 |
| FAB subtype | ||
| M0 | 11 | 5.3 |
| M1 | 45 | 21.8 |
| M2 | 65 | 31.6 |
| M4 | 25 | 12.1 |
| M5 | 48 | 23.3 |
| M6 | 6 | 2.9 |
| M7 | 1 | 0.5 |
| Unknown | 5 | 2.4 |
| Cytogenetic/FLT3-ITD risk group | ||
| Good | 24 | 11.7 |
| Intermediate (NN,-Y) | 62 | 30.1 |
| Poor (-5/5q-,-7/7q-,complex,FLT3-ITD) | 67 | 32.5 |
| Others | 46 | 22.3 |
| UNK/ND/failure | 7 | 3.4 |
| . | Overall population (n = 206) . | |
|---|---|---|
| . | No. . | % . |
| Age (years) at diagnosis | ||
| Median (range) | 48.0 (16.0-60.0) | |
| <30 | 21 | 10.2 |
| 30 to <40 | 36 | 17.5 |
| 40 to <50 | 59 | 28.6 |
| 50-60 | 90 | 43.7 |
| Sex | ||
| Male | 101 | 49.0 |
| Female | 105 | 51.0 |
| WHO-ECOG performance status | ||
| 0 | 122 | 59.2 |
| 1 | 74 | 35.9 |
| 2 | 7 | 3.4 |
| 3-4 | 3 | 1.5 |
| WBC (×109L) at diagnosis | ||
| Median (range) | 24.7 (0.5-312.5) | |
| <25 | 104 | 50.5 |
| 25-99.9 | 69 | 33.5 |
| ≥100 | 33 | 16.0 |
| FAB subtype | ||
| M0 | 11 | 5.3 |
| M1 | 45 | 21.8 |
| M2 | 65 | 31.6 |
| M4 | 25 | 12.1 |
| M5 | 48 | 23.3 |
| M6 | 6 | 2.9 |
| M7 | 1 | 0.5 |
| Unknown | 5 | 2.4 |
| Cytogenetic/FLT3-ITD risk group | ||
| Good | 24 | 11.7 |
| Intermediate (NN,-Y) | 62 | 30.1 |
| Poor (-5/5q-,-7/7q-,complex,FLT3-ITD) | 67 | 32.5 |
| Others | 46 | 22.3 |
| UNK/ND/failure | 7 | 3.4 |
FAB, French–American–British classification; ND, not determined; No., number; WBC, white blood cell count; WHO-ECOG, World Health Organization-Eastern Cooperative Oncology Group; UNK, unknown.